---
title: "REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights | RGNX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294683954.md"
description: "REGENXBIO Inc. (Nasdaq: RGNX) announced a conference call on August 6 at 8:00 a.m. ET to discuss its second-quarter 2026 financial results and operational highlights. The company, a biotechnology firm focused on gene therapy, will host the webcast for investors and analysts, with registration links and replay availability provided via their investor website."
datetime: "2026-08-03T03:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294683954.md)
  - [en](https://longbridge.com/en/news/294683954.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294683954.md)
generator: "portal-rs"
---

# REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights | RGNX Stock News

, /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 6, at 8:00 a.m. ET to discuss its financial results for the second quarter ended June 30, 2026, and operational highlights.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

**ABOUT** **REGENXBIO Inc.**  
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit **www.REGENXBIO.com.** 

**Contacts:**  
Dana Cormack  
Corporate Communications  
dcormack@regenxbio.com 

Investors:  
George E. MacDougall  
Investor Relations  
IR@regenxbio.com 

SOURCE REGENXBIO Inc.

### Related Stocks

- [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [4516.JP](https://longbridge.com/en/quote/4516.JP.md)
- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [NOT.DE](https://longbridge.com/en/quote/NOT.DE.md)

## Related News & Research

- [Regenxbio director Gregory Austin Ciongoli files initial beneficial ownership statement](https://longbridge.com/en/news/297240097.md)
- [REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli | RGNX Stock News](https://longbridge.com/en/news/296903302.md)
- [BUZZ-Regenxbio climbs as new director buys nearly $1 million of stock](https://longbridge.com/en/news/297313698.md)
- [RegenXBio Faces RGX-121 Clinical Hold, Refocuses Pipeline](https://longbridge.com/en/news/296834397.md)
- [REGENXBIO elects Gregory Ciongoli as director; Jean Bennett and. "Jerry" Karabelas resign](https://longbridge.com/en/news/296955594.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**